instruction
stringlengths 39
316
| response
stringlengths 121
336
| text
stringlengths 194
685
|
|---|---|---|
I’m interested in the median PFS of Daratumumab+Carfilzomib+Dexamethasone (DKd). | Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). | ### Instruction: I’m interested in the median PFS of Daratumumab+Carfilzomib+Dexamethasone (DKd).
### Response: Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). |
Could you tell me the median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd)? | Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). | ### Instruction: Could you tell me the median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd)?
### Response: Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). |
What is the median PFS rate for Daratumumab+Carfilzomib+Dexamethasone (DKd)? | Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). | ### Instruction: What is the median PFS rate for Daratumumab+Carfilzomib+Dexamethasone (DKd)?
### Response: Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) regimen? | Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) regimen?
### Response: Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). |
What is the median PFS rate in patients who have undergone Daratumumab+Carfilzomib+Dexamethasone (DKd) regimen? | Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). | ### Instruction: What is the median PFS rate in patients who have undergone Daratumumab+Carfilzomib+Dexamethasone (DKd) regimen?
### Response: Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) regimen? | Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) regimen?
### Response: Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). |
What’s the median PFS rate for patients receiving Daratumumab+Carfilzomib+Dexamethasone (DKd) regimen? | Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). | ### Instruction: What’s the median PFS rate for patients receiving Daratumumab+Carfilzomib+Dexamethasone (DKd) regimen?
### Response: Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). |
Could you provide the median Progression-Free Survival rate for patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) regimen? | Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) regimen?
### Response: Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). |
What is the median rate of Progression-Free Survival in patients who have been treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) regimen? | Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) regimen?
### Response: Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). |
Can you inform me about the median PFS rate in patients that were treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) regimen? | Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) regimen?
### Response: Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). |
What is the median PFS rate for patients that have undergone Daratumumab+Carfilzomib+Dexamethasone (DKd) regimen? | Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). | ### Instruction: What is the median PFS rate for patients that have undergone Daratumumab+Carfilzomib+Dexamethasone (DKd) regimen?
### Response: Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). |
Could you tell me the median Progression-Free Survival rate for patients who received Daratumumab+Carfilzomib+Dexamethasone (DKd) regimen? | Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Daratumumab+Carfilzomib+Dexamethasone (DKd) regimen?
### Response: Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). |
What’s the median rate of PFS in patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) regimen? | Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). | ### Instruction: What’s the median rate of PFS in patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) regimen?
### Response: Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). |
Can you share the median Progression-Free Survival rate in patients who have received Daratumumab+Carfilzomib+Dexamethasone (DKd) regimen? | Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Daratumumab+Carfilzomib+Dexamethasone (DKd) regimen?
### Response: Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). |
Can you tell me the median PFS for Carfilzomib+Dexamethasone (Kd)? | Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). | ### Instruction: Can you tell me the median PFS for Carfilzomib+Dexamethasone (Kd)?
### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). |
What’s the median PFS associated with Carfilzomib+Dexamethasone (Kd)? | Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). | ### Instruction: What’s the median PFS associated with Carfilzomib+Dexamethasone (Kd)?
### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). |
Could you provide the median PFS of Carfilzomib+Dexamethasone (Kd)? | Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). | ### Instruction: Could you provide the median PFS of Carfilzomib+Dexamethasone (Kd)?
### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). |
I’d like to know the median PFS of Carfilzomib+Dexamethasone (Kd). | Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). | ### Instruction: I’d like to know the median PFS of Carfilzomib+Dexamethasone (Kd).
### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). |
Do you have information on the median PFS of Carfilzomib+Dexamethasone (Kd)? | Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). | ### Instruction: Do you have information on the median PFS of Carfilzomib+Dexamethasone (Kd)?
### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). |
What is the median progression-free survival (PFS) for Carfilzomib+Dexamethasone (Kd)? | Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). | ### Instruction: What is the median progression-free survival (PFS) for Carfilzomib+Dexamethasone (Kd)?
### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). |
Can you inform me about the median PFS for Carfilzomib+Dexamethasone (Kd)? | Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). | ### Instruction: Can you inform me about the median PFS for Carfilzomib+Dexamethasone (Kd)?
### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). |
I’m interested in the median PFS of Carfilzomib+Dexamethasone (Kd). | Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). | ### Instruction: I’m interested in the median PFS of Carfilzomib+Dexamethasone (Kd).
### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). |
Could you tell me the median PFS for Carfilzomib+Dexamethasone (Kd)? | Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). | ### Instruction: Could you tell me the median PFS for Carfilzomib+Dexamethasone (Kd)?
### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). |
What is the median PFS rate for Carfilzomib+Dexamethasone (Kd)? | Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). | ### Instruction: What is the median PFS rate for Carfilzomib+Dexamethasone (Kd)?
### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Carfilzomib+Dexamethasone (Kd) regimen? | Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Carfilzomib+Dexamethasone (Kd) regimen?
### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). |
What is the median PFS rate in patients who have undergone Carfilzomib+Dexamethasone (Kd) regimen? | Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). | ### Instruction: What is the median PFS rate in patients who have undergone Carfilzomib+Dexamethasone (Kd) regimen?
### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Carfilzomib+Dexamethasone (Kd) regimen? | Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Carfilzomib+Dexamethasone (Kd) regimen?
### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). |
What’s the median PFS rate for patients receiving Carfilzomib+Dexamethasone (Kd) regimen? | Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). | ### Instruction: What’s the median PFS rate for patients receiving Carfilzomib+Dexamethasone (Kd) regimen?
### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). |
Could you provide the median Progression-Free Survival rate for patients treated with Carfilzomib+Dexamethasone (Kd) regimen? | Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Carfilzomib+Dexamethasone (Kd) regimen?
### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). |
What is the median rate of Progression-Free Survival in patients who have been treated with Carfilzomib+Dexamethasone (Kd) regimen? | Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Carfilzomib+Dexamethasone (Kd) regimen?
### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). |
Can you inform me about the median PFS rate in patients that were treated with Carfilzomib+Dexamethasone (Kd) regimen? | Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Carfilzomib+Dexamethasone (Kd) regimen?
### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). |
What is the median PFS rate for patients that have undergone Carfilzomib+Dexamethasone (Kd) regimen? | Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). | ### Instruction: What is the median PFS rate for patients that have undergone Carfilzomib+Dexamethasone (Kd) regimen?
### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). |
Could you tell me the median Progression-Free Survival rate for patients who received Carfilzomib+Dexamethasone (Kd) regimen? | Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Carfilzomib+Dexamethasone (Kd) regimen?
### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). |
What’s the median rate of PFS in patients treated with Carfilzomib+Dexamethasone (Kd) regimen? | Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). | ### Instruction: What’s the median rate of PFS in patients treated with Carfilzomib+Dexamethasone (Kd) regimen?
### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). |
Can you share the median Progression-Free Survival rate in patients who have received Carfilzomib+Dexamethasone (Kd) regimen? | Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Carfilzomib+Dexamethasone (Kd) regimen?
### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 15.2 months, with a 95% CI of (11.1, 19,9). |
Can you tell me the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd)? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). | ### Instruction: Can you tell me the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd)?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). |
What’s the median PFS associated with Daratumumab+Pomalidomide+Dexamethasone (DPd)? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). | ### Instruction: What’s the median PFS associated with Daratumumab+Pomalidomide+Dexamethasone (DPd)?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). |
Could you provide the median PFS of Daratumumab+Pomalidomide+Dexamethasone (DPd)? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). | ### Instruction: Could you provide the median PFS of Daratumumab+Pomalidomide+Dexamethasone (DPd)?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). |
I’d like to know the median PFS of Daratumumab+Pomalidomide+Dexamethasone (DPd). | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). | ### Instruction: I’d like to know the median PFS of Daratumumab+Pomalidomide+Dexamethasone (DPd).
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). |
Do you have information on the median PFS of Daratumumab+Pomalidomide+Dexamethasone (DPd)? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). | ### Instruction: Do you have information on the median PFS of Daratumumab+Pomalidomide+Dexamethasone (DPd)?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). |
What is the median progression-free survival (PFS) for Daratumumab+Pomalidomide+Dexamethasone (DPd)? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). | ### Instruction: What is the median progression-free survival (PFS) for Daratumumab+Pomalidomide+Dexamethasone (DPd)?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). |
Can you inform me about the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd)? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). | ### Instruction: Can you inform me about the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd)?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). |
I’m interested in the median PFS of Daratumumab+Pomalidomide+Dexamethasone (DPd). | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). | ### Instruction: I’m interested in the median PFS of Daratumumab+Pomalidomide+Dexamethasone (DPd).
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). |
Could you tell me the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd)? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). | ### Instruction: Could you tell me the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd)?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). |
What is the median PFS rate for Daratumumab+Pomalidomide+Dexamethasone (DPd)? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). | ### Instruction: What is the median PFS rate for Daratumumab+Pomalidomide+Dexamethasone (DPd)?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). |
What is the median PFS rate in patients who have undergone Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). | ### Instruction: What is the median PFS rate in patients who have undergone Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). |
What’s the median PFS rate for patients receiving Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). | ### Instruction: What’s the median PFS rate for patients receiving Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). |
Could you provide the median Progression-Free Survival rate for patients treated with Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). |
What is the median rate of Progression-Free Survival in patients who have been treated with Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). |
Can you inform me about the median PFS rate in patients that were treated with Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). |
What is the median PFS rate for patients that have undergone Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). | ### Instruction: What is the median PFS rate for patients that have undergone Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). |
Could you tell me the median Progression-Free Survival rate for patients who received Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). |
What’s the median rate of PFS in patients treated with Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). | ### Instruction: What’s the median rate of PFS in patients treated with Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). |
Can you share the median Progression-Free Survival rate in patients who have received Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 12.4 months, with a 95% CI of (8.3, 19.3). |
Can you tell me the median PFS for Pomalidomide+Dexamethasone (Pd)? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). | ### Instruction: Can you tell me the median PFS for Pomalidomide+Dexamethasone (Pd)?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). |
What’s the median PFS associated with Pomalidomide+Dexamethasone (Pd)? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). | ### Instruction: What’s the median PFS associated with Pomalidomide+Dexamethasone (Pd)?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). |
Could you provide the median PFS of Pomalidomide+Dexamethasone (Pd)? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). | ### Instruction: Could you provide the median PFS of Pomalidomide+Dexamethasone (Pd)?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). |
I’d like to know the median PFS of Pomalidomide+Dexamethasone (Pd). | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). | ### Instruction: I’d like to know the median PFS of Pomalidomide+Dexamethasone (Pd).
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). |
Do you have information on the median PFS of Pomalidomide+Dexamethasone (Pd)? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). | ### Instruction: Do you have information on the median PFS of Pomalidomide+Dexamethasone (Pd)?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). |
What is the median progression-free survival (PFS) for Pomalidomide+Dexamethasone (Pd)? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). | ### Instruction: What is the median progression-free survival (PFS) for Pomalidomide+Dexamethasone (Pd)?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). |
Can you inform me about the median PFS for Pomalidomide+Dexamethasone (Pd)? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). | ### Instruction: Can you inform me about the median PFS for Pomalidomide+Dexamethasone (Pd)?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). |
I’m interested in the median PFS of Pomalidomide+Dexamethasone (Pd). | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). | ### Instruction: I’m interested in the median PFS of Pomalidomide+Dexamethasone (Pd).
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). |
Could you tell me the median PFS for Pomalidomide+Dexamethasone (Pd)? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). | ### Instruction: Could you tell me the median PFS for Pomalidomide+Dexamethasone (Pd)?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). |
What is the median PFS rate for Pomalidomide+Dexamethasone (Pd)? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). | ### Instruction: What is the median PFS rate for Pomalidomide+Dexamethasone (Pd)?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). |
What is the median PFS rate in patients who have undergone Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). | ### Instruction: What is the median PFS rate in patients who have undergone Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). |
What’s the median PFS rate for patients receiving Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). | ### Instruction: What’s the median PFS rate for patients receiving Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). |
Could you provide the median Progression-Free Survival rate for patients treated with Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). |
What is the median rate of Progression-Free Survival in patients who have been treated with Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). |
Can you inform me about the median PFS rate in patients that were treated with Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). |
What is the median PFS rate for patients that have undergone Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). | ### Instruction: What is the median PFS rate for patients that have undergone Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). |
Could you tell me the median Progression-Free Survival rate for patients who received Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). |
What’s the median rate of PFS in patients treated with Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). | ### Instruction: What’s the median rate of PFS in patients treated with Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). |
Can you share the median Progression-Free Survival rate in patients who have received Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.9 months, with a 95% CI of (5.5, 9.3). |
Can you tell me the median PFS for Subcutaneous Daratumumab (Dara SC)? | Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). | ### Instruction: Can you tell me the median PFS for Subcutaneous Daratumumab (Dara SC)?
### Response: Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). |
What’s the median PFS associated with Subcutaneous Daratumumab (Dara SC)? | Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). | ### Instruction: What’s the median PFS associated with Subcutaneous Daratumumab (Dara SC)?
### Response: Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). |
Could you provide the median PFS of Subcutaneous Daratumumab (Dara SC)? | Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). | ### Instruction: Could you provide the median PFS of Subcutaneous Daratumumab (Dara SC)?
### Response: Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). |
I’d like to know the median PFS of Subcutaneous Daratumumab (Dara SC). | Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). | ### Instruction: I’d like to know the median PFS of Subcutaneous Daratumumab (Dara SC).
### Response: Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). |
Do you have information on the median PFS of Subcutaneous Daratumumab (Dara SC)? | Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). | ### Instruction: Do you have information on the median PFS of Subcutaneous Daratumumab (Dara SC)?
### Response: Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). |
What is the median progression-free survival (PFS) for Subcutaneous Daratumumab (Dara SC)? | Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). | ### Instruction: What is the median progression-free survival (PFS) for Subcutaneous Daratumumab (Dara SC)?
### Response: Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). |
Can you inform me about the median PFS for Subcutaneous Daratumumab (Dara SC)? | Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). | ### Instruction: Can you inform me about the median PFS for Subcutaneous Daratumumab (Dara SC)?
### Response: Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). |
I’m interested in the median PFS of Subcutaneous Daratumumab (Dara SC). | Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). | ### Instruction: I’m interested in the median PFS of Subcutaneous Daratumumab (Dara SC).
### Response: Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). |
Could you tell me the median PFS for Subcutaneous Daratumumab (Dara SC)? | Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). | ### Instruction: Could you tell me the median PFS for Subcutaneous Daratumumab (Dara SC)?
### Response: Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). |
What is the median PFS rate for Subcutaneous Daratumumab (Dara SC)? | Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). | ### Instruction: What is the median PFS rate for Subcutaneous Daratumumab (Dara SC)?
### Response: Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Subcutaneous Daratumumab (Dara SC) regimen? | Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Subcutaneous Daratumumab (Dara SC) regimen?
### Response: Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). |
What is the median PFS rate in patients who have undergone Subcutaneous Daratumumab (Dara SC) regimen? | Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). | ### Instruction: What is the median PFS rate in patients who have undergone Subcutaneous Daratumumab (Dara SC) regimen?
### Response: Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Subcutaneous Daratumumab (Dara SC) regimen? | Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Subcutaneous Daratumumab (Dara SC) regimen?
### Response: Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). |
What’s the median PFS rate for patients receiving Subcutaneous Daratumumab (Dara SC) regimen? | Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). | ### Instruction: What’s the median PFS rate for patients receiving Subcutaneous Daratumumab (Dara SC) regimen?
### Response: Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). |
Could you provide the median Progression-Free Survival rate for patients treated with Subcutaneous Daratumumab (Dara SC) regimen? | Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Subcutaneous Daratumumab (Dara SC) regimen?
### Response: Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). |
What is the median rate of Progression-Free Survival in patients who have been treated with Subcutaneous Daratumumab (Dara SC) regimen? | Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Subcutaneous Daratumumab (Dara SC) regimen?
### Response: Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). |
Can you inform me about the median PFS rate in patients that were treated with Subcutaneous Daratumumab (Dara SC) regimen? | Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Subcutaneous Daratumumab (Dara SC) regimen?
### Response: Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). |
What is the median PFS rate for patients that have undergone Subcutaneous Daratumumab (Dara SC) regimen? | Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). | ### Instruction: What is the median PFS rate for patients that have undergone Subcutaneous Daratumumab (Dara SC) regimen?
### Response: Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). |
Could you tell me the median Progression-Free Survival rate for patients who received Subcutaneous Daratumumab (Dara SC) regimen? | Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Subcutaneous Daratumumab (Dara SC) regimen?
### Response: Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). |
What’s the median rate of PFS in patients treated with Subcutaneous Daratumumab (Dara SC) regimen? | Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). | ### Instruction: What’s the median rate of PFS in patients treated with Subcutaneous Daratumumab (Dara SC) regimen?
### Response: Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). |
Can you share the median Progression-Free Survival rate in patients who have received Subcutaneous Daratumumab (Dara SC) regimen? | Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Subcutaneous Daratumumab (Dara SC) regimen?
### Response: Patients treated with the Subcutaneous Daratumumab (Dara SC) have a median Progression-Free Survival (PFS) rate of 5.6 months, with a 95% CI of (4.7, 7.6). |
Can you tell me the median PFS for Intravenous Daratumumab (Dara IV)? | Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). | ### Instruction: Can you tell me the median PFS for Intravenous Daratumumab (Dara IV)?
### Response: Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). |
What’s the median PFS associated with Intravenous Daratumumab (Dara IV)? | Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). | ### Instruction: What’s the median PFS associated with Intravenous Daratumumab (Dara IV)?
### Response: Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.